Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.
Source: US Top News and Analysis
Related Posts
Average IRS tax refund is up 10.8%, new filing data shows
The average IRS tax refund is up 10.8%, based on new filing data. Here’s what…
Trump: ‘I don’t want to do a ceasefire’ in Iran war
President Donald Trump said the U.S. was ‘obliterating’ Iran in the conflict. Source: US Top…
Figma’s stock drops 12% in two days after Google releases ‘vibe design’ product
Figma’s stock has been getting hammered on concerns about AI, and Google’s new design product…